Gender Male
Investor Type
Dr. Benjamin Miles completed his PhD in Nanophysics at the University of Bristol in 2016. Following his PhD, Dr. Miles joined Ziylo as Lead Physicist to commercialise a diabetes therapeutic later acquired for $800m by Novo Nordisk.